TCGA-56-A4BW-01A-11R-A24H-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 55
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.500
- KRAS_SIGNALING_DN+0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.280
- MYOGENESIS+0.240
- ANGIOGENESIS+0.230
- G2M_CHECKPOINT+0.230
- ESTROGEN_RESPONSE_LATE+0.220
- E2F_TARGETS+0.210
- SPERMATOGENESIS+0.210
- INTERFERON_GAMMA_RESPONSE+0.180
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.530
- UNFOLDED_PROTEIN_RESPONSE-0.500
- MYC_TARGETS_V2-0.480
- DNA_REPAIR-0.460
- MYC_TARGETS_V1-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.440
- ADIPOGENESIS-0.420
- PROTEIN_SECRETION-0.400
- MTORC1_SIGNALING-0.380
- CHOLESTEROL_HOMEOSTASIS-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1321674 | GTEX | — | 0.851 |
| 2 | SRR1338301 | GTEX | — | 0.829 |
| 3 | SRR1489155 | GTEX | — | 0.827 |
| 4 | BS_44A3ES23 | Med | Medulloblastoma | 0.822 |
| 5 | SRR1390582 | GTEX | — | 0.813 |
| 6 | SRR615515 | GTEX | — | 0.813 |
| 7 | R402 | — | — | 0.813 |
| 8 | BS_97M1E2DW | Diffuse intrinsic pontine glioma | — | 0.813 |
| 9 | SRR658188 | GTEX | — | 0.810 |
| 10 | SRR1421093 | GTEX | — | 0.808 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.500 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.430 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| COAGULATION | 0.070 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.060 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |